U.S. senators criticize SF company over Super Bowl commercial
Hims and Hers is a telehealth firm based in San Francisco
U.S. Senators Dick Durbin and Roger Marshall are criticizing a Super Bowl commercial by the company
SAN FRANCISCO - Outside the game, commercials are a big part of Super Bowl Sunday. Companies pay large amounts of money for their advertisements. One company based in the Bay Area has already released its commercial, and it's drawing criticism from lawmakers in Washington.
Hims and Hers, headquartered in San Francisco, is a telehealth firm, and in their latest ad, they promote a weight-loss drug similar to Ozempic.
U.S. Senators Dick Durbin (D-IL) and Roger Marshall (R-KS) sent a bipartisan letter to the FDA about the advertisement, accusing the ad of misleading patients by "omitting any safety or side effect information when prompting a specific type of weight loss medication," according to a statement on Durbin's website.
"An upcoming Super Bowl advertisement…appears to showcase a company's ability to prescribe and dispense GLP-1 medications to patients, including with text and claims about weight loss drugs, and imagery of an injection pen with distinctive characteristics reflective of an existing brand-name medication. However, nowhere in this promotion is there any side effect disclosure, risk, or safety information as would be typically required in a pharmaceutical advertisement," the senators wrote in part.
The other side
KTVU reached out to the San Francisco-based firm about the controversy.
"We agree with the Senators, Durbin and Marshall, on the value of compounding and telehealth when it comes to expanding much-needed access to personalized care. We are complying with existing law and are happy to continue working with Congress and the new Administration to fix the broken health system and ensure that patients have choices for quality, safe, and affordable healthcare," Hims and Hers said in response.
The Source
Senator Durbin's website, Hims and Hers spokesperson
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Wegovy and beyond: Will weight-loss drugs change the way people look at obesity?
Wegovy, the blockbuster weight-loss drug, is now available in Singapore more than two years after it was approved by the Health Sciences Authority. But its arrival here sparks a deeper conversation about who should take it, how it makes us rethink obesity and weight loss, and whether weight-loss drugs are a magic bullet. Earlier in July, pharmaceutical firm Novo Nordisk, which makes Wegovy, announced in a statement that the injectable drug is now available with prescription from any licensed physician at hospitals and clinics across Singapore. The global hype around Wegovy, which is made for weight loss, stemmed from Ozempic, which was created as an anti-diabetic drug. The latter garnered a lot of attention on social media a few years ago after its users, who weren't all diabetics, showed off their considerable weight loss. What connects Wegovy and Ozempic – besides both being made by Novo Nordisk – is that they contain the active ingredient semaglutide. Mimicking the natural hormone glucagon-like peptide-1, semaglutide regulates blood sugar levels, curbs the appetite and induces the sensation of fullness. One of the differences? Wegovy has a higher maximum dosage of 2.4mg than Ozempic's 2mg. While the benefits have been laid out, what should those considering Wegovy look out for? To answer these questions on this episode of The Usual Place, I have: Senior consultant endocrinologist Dr Sue-Anne Toh from Novi Health, a specialist medical clinic and health-tech company. She has more than 20 years of experience in internal medicine, diabetes, and metabolic health. Her patient Farhan Hanis, a 26-year-old university student and a former plus-sized model. He started on Wegovy about two months ago. General practitioner Dr Bosty Chan, who co-founded health telemedicine providers Sire and Dame, which offers weight management as part of a suite of services. Tune in at 12pm SGT/HKT to watch the stream, and share your thoughts on our revamped YouTube channel. Follow The Usual Place Podcast live at noon every Thursday and get notified for new episode drops: Channel: Apple Podcasts: Spotify: YouTube: Source: The Straits Times © SPH Media Limited. Permission required for reproduction Discover how to enjoy other premium articles here
Yahoo
6 hours ago
- Yahoo
Possible metal found in ground beef: Michigan company issues recall across 5 states
A Michigan-based meat company recalled more than 1,000 pounds of fully cooked ground beef after a customer reported finding pieces of metal in the product, it said in a release. Ada Valley Meat Company on Tuesday said recalled products were shipped to businesses and distributors across five states: California, Delaware, Illinois, Michigan and Pennsylvania. The affected items came in 20-pound boxes containing four 5-pound bags of "Ada Valley Fully Cooked Ground Beef" from specific lots -- pack date May 28 with lot code 35156 and pack date May 30 with lot code 35157 -- the company said. The products subject to recall also bear establishment number "EST. 10031" inside the U.S. Department of Agriculture (USDA) mark of inspection, it said. While no injuries have been reported, food safety officials are concerned that some of the recalled products might still be in institutional freezers, Ada Valley noted. "We are taking this step out of an abundance of caution and in line with our core value: the safety and trust of our customers come first," Gerrit Rozeboom, the company's president, said in a statement sent to ABC News. MORE: High Noon voluntarily recalls some vodka seltzer drinks that were mislabeled as Celsius energy drinks The USDA Food Safety and Inspection Service advised institutions not to serve these products and instead throw them away or return them to where they were purchased. "We are working closely with regulators to investigate the issue and have already implemented additional safety measures and quality checks to prevent future occurrences," Rozeboom told ABC News. Customers with questions about the recall can contact the USDA Meat and Poultry Hotline at 888-674-6854 or email MPHotline@
Yahoo
7 hours ago
- Yahoo
NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?
Health-related stocks are not having a good day. First, America's largest health insurance provider, UnitedHealth Group (NYSE: UNH), saw its stock drop more than 4% this morning after the company announced disappointing second-quarter results and a full-year 2025 forecast that concerned investors. And now, the Danish pharmaceutical giant Novo Nordisk A/S, whose shares (NYSE: NVO) trade on the New York Stock Exchange, is seeing its stock price plunge, too. The real reason a staggering 40% of U.S. homeowners are mortgage-free Tsunami warning tracker: Map and online tool let you follow alerts in real time after massive earthquake Figma's IPO date is close. The stock could trade even higher after the design startup's latest move Currently, NVO shares are down more than 20% at the time of this writing. But unlike UnitedHealth Group, Novo Nordisk has not reported its most recent quarterly results. So what's sending its shares lower? Here's what you need to know. Novo Nordisk cuts full-year 2025 guidance The main driver of Novo Nordisk's significant share price fall today is the company's announcement that it is revising its previously published sales growth and operating profit growth for its full fiscal year 2025. On May 7, Novo Nordisk stated that it expected full-year fiscal 2025 sales growth to be between 13% and 21%. At the same time, it said it expected its operating profit growth to be between 16% and 24%. Now, however, the company had drastically cut both forecasts. Novo Nordisk now says it expects full-year fiscal 2025 sales growth to be between 8% and 14% and operating profit growth to be between 10% and 16%. In a statement, the company said its 'lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025.' This lowered growth is due to lower growth expectations for its GLP-1 weight loss and diabetes drugs, Wegovy and Ozempic, in the U.S. market. 'For Wegovy in the US, the sales outlook reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition,' the company said. It added that as far as Ozempic was concerned, 'the updated outlook is negatively impacted by competition in the U.S.' Novo Nordisk's main competitor in the GLP-1 arena is the American pharmaceutical giant Eli Lilly, who makes the drugs Mounjaro and Zepbound. Novo Nordisk names new CEO Besides revising its 2025 growth forecasts downward, Novo Nordisk also made another announcement today: It named a new CEO. However, this announcement probably had little to do with the stock's fall this morning. Back in May, Novo Nordisk announced that its longtime CEO Lars Fruergaard Jørgensen would be stepping aside. At the time, the company cited its declining share price as one of the reasons for the CEO shakeup. It also said Jørgensen would stay on as CEO until a successor was found. Now, one has been. Today, Novo Nordisk announced that Maziar Mike Doustdar will be assuming the position of president and chief executive officer, effective August 7, 2025. Doustdar is currently the company's executive vice president of international operations. Announcing Doustdar's ascent to the CEO role, Novo Nordisk chair Helge Lund said: 'This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Doustdar will officially take over as CEO one day after the company reports its second quarter 2025 results on August 6. Novo Nordisk shares have fallen dramatically since last summer While the GLP-1 drugs Wegovy and Ozempic have been a massive source of growth and profits at Novo Nordisk in the first half of this decade, recently, the company has faced increased competition in the GLP-1 marketplace, which has partly contributed to investor concerns. Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down more than 57%. And since the beginning of 2025, the company's share price has declined more than 35%. As of the time of this writing, NVO shares are down just over 20% this morning to $55.17 per share. This post originally appeared at to get the Fast Company newsletter: Sign in to access your portfolio
